Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2003

View Archived Issues

French team reports inhibitors of atheroma formation

CV Therapeutics claims adenosine A2B antagonists for asthma and other uses

Orally active DHFR inhibitors discovered at Essential Therapeutics

Dong Wha reports novel agents for hepatitis B and C infection

New antidiabetic PTP inhibitors in Novo Nordisk pipeline

Aventis claims novel factor VIIa inhibitors

Japanese researchers identify novel peptides with anti-HIV activity

Tucaresol reported to restore immune function in HAART-treated HIV patients

Good long-term efficacy profile reported for abacavir combined with lamivudine

HIV susceptibility to tipranavir maintained following tipranavir/ritonavir therapy

Humanized MAbs targeting CEA available for licensing from NIH

Atazanavir in healthy subjects and HIV-infected patients

Atugen identifies novel cancer target

Atugen and metaGen sign target validation agreement

Kyowa Hakko establishes U.S. antibody business

Patient enrollment completed in phase II ALS study of EHT-0201

Animal toxicology program completed for systemic Reolysin

Development of oral botulinum toxin vaccine commences at DOR BioPharma

Further milestone payment made under D-63153 development agreement

Medivir presents 2002 summary

Deramciclane will not be developed for GAD indication

AZD-3582 does not reach primary endpoint in a phase II study

Superior survival compared to Atgam not achieved in GvHD patients treated with ABX-CBL

New phenylisoxazolines active against resistant Gram-positive pathogens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...